Do you have a loved one with agitation associated with Alzheimer’s dementia?
Is someone you care for with Alzheimer's dementia exhibiting excessive motor activity, verbal and/or physical aggression?
If so, they may qualify for the ASPECT™ clinical research study. The purpose of this study is to evaluate the safety and effectiveness of an investigational drug for agitation associated with Alzheimer’s dementia.
The ASPECT study can help us learn more about a potential treatment for agitation in patients with Alzheimer’s dementia.
To be eligible for this study, a potential participant must:
Be between the ages of 50 and 90 [inclusive]
Have a diagnosis of probable Alzheimer’s dementia
Have moderate-to-severe agitation that interferes with their daily life
Have a reliable carer who spends a minimum of 2 hours per day, 4 days per week with them and is willing and able to comply with all study procedures
Other eligibility criteria will apply.
Those who qualify will receive study-required medical care and study drug at no cost.
About Agitation associated with Alzheimer’s Dementia
These are just some of the many reasons why more research on the disease is needed.
Sources:
1 Cummings J, et al. “Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition.” International Psychogeriatrics, 27:1, 7–17. 2015. https://www.ncbi.nlm.nih.gov/pubmed/25311499
2 Knapp M, et al. “Predictors of care home and hospital admissions and their costs for older people with Alzheimer’s disease: findings from a large London case register.” BMJ Open, 6:11, 1-15. 2016. https://bmjopen.bmj.com/content/bmjopen/6/11/e013591.full.pdf
3 DeTure MA, et al. The neuropathological diagnosis of Alzheimer’s disease. Molecular Neurodegeneration. 2019;14:32;doi.org/10.1186/s13024-019-0333-5
4 Alzheimer’s Association. “2017 Alzheimer’s Disease Facts and Figures.” Alzheimer’s & Dementia, 13: 325-373. April 2017. https://www.sciencedirect.com/science/article/pii/S1552526017300511?viewFullText=true
5 Laybourne A, et al. “Carer coping and resident agitation as predictors of quality of life in care home residents living with dementia: Managing Agitation and Raising Quality of Life (MARQUE) English national care home prospective cohort study.” International Journal Of Geriatric. Psychiatry, 34:106-113. 2018. https://www.ncbi.nlm.nih.gov/pubmed/30276865
6 Rabins P, et al. “Neuropsychiatric symptoms at baseline predict shorter time to severe dementia in a population-based sample of incident Alzheimer’s disease: The Cache County dementia progression study.” Alzheimer’s and Dementia, supplement, 8.4: 126-127. 2012. https://www.alzheimersanddementia.com/article/S1552-5260(12)00465-7/abstract
7 Peters M, et al. “Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: The Cache County Dementia Progression Study.”172(5): 460-5. 2015. https://www.ncbi.nlm.nih.gov/pubmed/25585033.